Virax Biolabs Group Ltd

Virax Biolabs is a global biotechnology holding company incorporated in the Cayman Islands, operating since 2013. It conducts most of its business through subsidiaries in the United Kingdom, the United States, and China. The company focuses on the prevention, detection, diagnosis, and risk management of viral diseases, specifically in T cell In Vitro Diagnostics. Virax Biolabs is developing and manufacturing tests to predict adaptive immunity to viral diseases and identify individuals with T cell exhaustion and chronic inflammation linked to post-viral syndromes. Its goal is to protect people from viral diseases and aid in the early diagnosis of post-viral syndromes through diagnostic tests and adaptive immunity tests. The company is developing ViraxImmune, an immunology profiling platform designed to assess individual immune risk profiles against major global viral diseases and assist in the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. A T cell Test is being developed under the ViraxImmune brand, for which regulatory approval will be sought. This platform and T cell Tests are intended to assist in threat analysis of major global viruses and help with early diagnosis of conditions linked to T cell exhaustion and chronic inflammation, such as chronic fatigue. Initial focus areas include post-viral syndromes related to SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1). The company is preparing a Q-submission under the U.S.